Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how BioMarin performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Net product revenues: $984.39 million versus the eight-analyst average estimate of $914.12 million. The reported number represents a year-over-year change of +21.1%.
• Revenues- Royalty and other revenues: $5.32 million compared to the $8.21 million average estimate based on eight analysts. The reported number represents a change of -57.2% year over year.
• Revenues- Net Product Revenues- NAGLAZYME: $135 million compared to the $125.91 million average estimate based on seven analysts. The reported number represents a change of +4.7% year over year.
• Revenues- Net Product Revenues- VIMIZIM: $194 million compared to the $205.82 million average estimate based on seven analysts. The reported number represents a change of -9.8% year over year.
• Revenues- Net Product Revenues- PALYNZIQ: $135 million versus $112.75 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +27.4% change.
• Revenues- Net Product Revenues- VOXZOGO: $253 million versus the seven-analyst average estimate of $238.2 million. The reported number represents a year-over-year change of +14.5%.
• Revenues- Net Product Revenues- KUVAN: $24 million versus the seven-analyst average estimate of $17.25 million. The reported number represents a year-over-year change of -11.1%.
• Revenues- Net Product Revenues- ALDURAZYME: $44 million versus the seven-analyst average estimate of $52.41 million. The reported number represents a year-over-year change of -21.4%.
• Revenues- Net Product Revenues- BRINEURA: $51 million versus $50.06 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +4.1% change.

View all Key Company Metrics for BioMarin here>>>

Shares of BioMarin have returned +0.3% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research